Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with a type of non-Hodgkin's lymphoma (a blood cancer) that has come back or stopped responding to treatment, confirmed by lab testing to have a specific protein marker called CD19 on the cancer cells.
- People whose cancer cells test positive for a protein called CD20 who have already received the standard targeted treatment for that.
- People who have measurable signs of the disease that can be tracked during the trial, assessed using a specific set of medical guidelines (Lugano 2014 standards).
- People aged 18 or older.
- People whose doctors expect them to live for more than 3 months.
- People who are generally able to carry out daily activities, with only mild limitations due to illness (rated 0 or 1 on a standard medical scale called the ECOG scale).
- Women who could become pregnant must have a negative blood pregnancy test before starting the trial and must agree to use effective contraception throughout the trial until the last follow-up appointment.
- People who choose to take part voluntarily and sign a consent form agreeing to join the trial.
Who may not be able to join:
- People whose doctors believe their lymphoma has spread to the digestive system or brain/spinal cord in a way that could make this treatment risky.
- People who are experiencing a reaction where transplanted cells are attacking their body (graft-versus-host disease) and need medication to suppress their immune system, or people who have an autoimmune disease.
- People who have received chemotherapy or radiotherapy within three days before the blood collection stage of the trial.
- People who have taken steroid tablets or injections (not including inhaled steroids) within 5 days before the blood collection stage.
- People who have taken medications that stimulate the bone marrow to produce blood cells within 5 days before the blood collection stage.
- People who have previously received any type of gene therapy.
- People with a history of epilepsy or other conditions affecting the brain or nervous system.
- People with an active Hepatitis B or Hepatitis C infection.
- People who have had another type of cancer at any point in the past 5 years.
- People who have had an active or uncontrolled infection requiring full-body (systemic) treatment within 14 days before enrolling in the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yuqin Song, MD, PhD, Peking University Cancer Hospital & Institute
Phone: +8615801390058
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective Response Rate(ORR) at 90 days
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.